$2.10
-4.55%
N/A-$0.10
헬스케어
생명공학
NASDAQ
활발히 거래 중
CalciMedica, Inc.는 캘리포니아주 라호야에 본사를 둔 임상 단계 생명공학 기업으로, 현재는 적절한 치료제가 부족한 생명을 위협하는 염증성 질환을 위한 치료제 개발에 집중하고 ...
CalciMedica, Inc.는 캘리포니아주 라호야에 본사를 둔 임상 단계 생명공학 기업으로, 현재는 적절한 치료제가 부족한 생명을 위협하는 염증성 질환을 위한 치료제 개발에 집중하고 ...
CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, dedicated to developing innovative therapies for life-threatening inflammatory diseases that currently lack adequate treatment options. The company's proprietary platform targets calcium release-activated calcium (CRAC) channels, which play a pivotal role in immune cell activation and inflammatory responses. By inhibiting these channels, CalciMedica aims to modulate the immune system and protect against cellular and tissue damage in severe conditions. The lead drug candidate, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor currently in clinical development for acute pancreatitis, including its asparaginase-associated form, and acute kidney injury. These indications represent significant unmet medical needs with limited therapeutic options. The company also explores applications in other inflammatory and immunologic diseases. On the business side, CalciMedica went public in June 2023 and is listed on the NASDAQ Capital Market under the ticker CALC. The company has a market capitalization of approximately $9.76 million as of the latest data, with a negative enterprise value, reflecting its pre-revenue stage. Financially, CalciMedica has no revenue, and its operating expenses are primarily directed towards research and development and general administrative activities. The company had 16 full-time employees as of the most recent report, emphasizing a lean operational structure typical of early-stage biotech firms. Key leadership includes CEO A. Rachel Leheny, who has over 30 years of life sciences experience, along with co-founder and Chief Scientific Officer Kenneth Stauderman. The executive team brings extensive expertise in drug development and corporate strategy. CalciMedica's future prospects hinge on the successful advancement of Auxora through clinical trials and potential regulatory approval, which could address critical needs in acute inflammatory conditions. The company's commitment to CRAC channel inhibition as a novel mechanism offers a differentiated approach in the biotechnology landscape, with the potential to improve patient outcomes in devastating diseases.